Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 13  |  Issue : 5  |  Page : 833-836

The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis


1 Department of Oncology Surgery, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China
2 Department of Oncology Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China

Correspondence Address:
Suyang Guo
Department of Oncology Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_424_17

Rights and Permissions

Objective: The aim of this study was to evaluate the secreted protein acidic and rich in cysteine (SPARC) expression in breast cancer tissue and its association with patients' clinical pathology characteristics and prognosis. Materials and Methods: Eight-eight cases with confirmed diagnosis of breast cancer who received operation from January 2010 to February 2016 were included in this study. The SPARC expression in cancer tissue was examined by immunohistochemical method. The SPARC expression status, clinical pathology characteristics, and prognosis of included patients were recorded and evaluated. Results: SPARC protein was mainly expressed in cytoplasm and stroma of tumor tissue with dark brown and purple stain. The SPARC protein-positive expression rate was 69.3% (61/88) in cancer tissue. The positive expression of SPARC in breast tissues was not significantly correlated with age, menstruation status, tumor, node, and metastasis stage, tumor size, progesterone level, and HER-2 status (P > 0.05). However, SPARC protein-positive expression was correlated with tumor differentiation (P < 0.05), estrogen receptor expression (P < 0.05), and lymph node metastasis (P < 0.05). The 3-year disease-free survival (DFS) was 60.8% and 71.2% for SPARC-positive and -negative groups with no statistical difference (P > 0.05); there was no statistical difference of disease progression risk between the SPARC-positive and -negative groups (hazard ratio = 1.78, 95% confidence interval: 0.80–3.57, P > 0.05). However, SPARC-positive and -negative patients have shown a trend of DFS difference. Conclusion: SPARC is closely related to the development of breast cancer and can be used as a tumor marker for breast cancer recurrence.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed862    
    Printed12    
    Emailed0    
    PDF Downloaded53    
    Comments [Add]    

Recommend this journal